Active substance combination for systemic treatment of inflammation and malicious disorders
The present invention relates to a combination of two natural and a semi-synthetic active ingredient, and to a pharmaceutical composition thereof.
New ppv1 strain and uses thereof
The present invention relates to a newly isolated strain of PPV1. The invention further relates to the use of the novel strain PPV1 for eliciting an immune response. The invention further relates to the use of the new strain PPV1 for the preparation of vaccine compositions.
Immunological methods for detection of porcine parvovirus 2 (ppv2) and ppv2 antibodies
Porcine parvovirus 2 (PPV2) is a member of a recently discovered worldwide group of porcine parvoviruses and is often detected in the background of respiratory symptoms, suggesting a pathological role for the virus in the disease.
Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO) / vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases
The invention relates to a compound having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein- 1 (VAP-I), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO/VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.
Use of kynurenic acid amide derivatives for the treatment of huntington’s disease
The present invention is directed to kynurenic acid amide analogues as well as salts thereof, to pharmaceutical compositions containing said compounds for use for curing the symptoms of Huntingtons’s disease as well as for preventing the development of said symptoms.
Recent posts
Danubia Wins First Place of the Companies For The Future Award 2024
TRADEMARK PROTECTION OF A COLOUR AGAINST THE SHADE OF THE SAME COLOUR ‘MILKA’
REIMBURSEMENT OF ENRICHMENT ACHIEVED BY TRADEMARK INFRINGEMENT
Measuring and reflecting the utilization of research results in university rankings
NOTICE OF TERMINATION FOR A LICENSE AGREEMENT